

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,064	04/27/2001	Veronique Gruber	18433/2002	1669
29933	7590 07/01/2002			
PALMER & DODGE, LLP		EXAMIN	NER	
111 HUNTIN	M. WILLIAMS GTON AVENUE		QIAN, CELINE X	
BOSTON, MA	A 02199		ART UNIT	PAPER NUMBER
			1636	G
			DATE MAILED: 07/01/2002	. I

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/845,064	GRUBER ET AL.				
•	Office Action Summary	Examiner	Art Unit				
		Celine Qian	1636				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status		- 4 '' 00 04					
1)⊠	Responsive to communication(s) filed on $\underline{2}$						
2a)	· · · · · · · · · · · · · · · · · · ·	This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims						
4)🖾	Claim(s) 1-53 and 55 is/are pending in the	application.					
	4a) Of the above claim(s) is/are withd	rawn from consideration.					
5)	Claim(s) is/are allowed.						
6)	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
	Claim(s) <u>1-53 and 55</u> are subject to restriction	on and/or election requirement.					
• •	on Papers						
	9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
40)	If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.						
		LXAITIIIICI.					
_	under 35 U.S.C. §§ 119 and 120	sian priority under 35 H S C & 110/	(a)_(d) or (f)				
	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)	 a) ☐ All b) ☐ Some * c) ☐ None of: 1.☐ Certified copies of the priority documents have been received. 						
			tion No				
	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) 🔲 /	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
15) <u></u>	 a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)							
2) Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(5) Notice of Informa	ary (PTO-413) Paper No(s) Il Patent Application (PTO-152)				
LL C Potent and	Trademark Office						

Application/Control Number: 09/845,064

Art Unit: 1636

DETAILED ACTION

Claims 1-53 and 55 are pending in the application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 2-10, drawn to a vector comprising one origin of replication, classified in class 435, subclass 320.1.
- II. Claims 11-15, drawn to a vector comprising two origin of replication, classified in class 536, subclass 23.1.
- III. Claims 17-24, drawn to a binary plasmid vector comprising a T-DNA sequence with left and right border, class 536, subclass 24.2.
- IV. Claims 30 and 31, drawn to a vector comprising an expression promoting nucleic acid sequence, class 536, subclass 24.1.
- V. Claims 37-44, 53 and 55 drawn to a transgenic plant, and a method of making said transgenic plant, class 800, subclass 278.

Claims 1, 16, 25-29, 32-36, and 45-52 are generic to Groups I-IV and will be examined in so far as it reads on the elected subject matter. If either Groups I-IV is elected, Applicants are further required to elect one SEQ ID number comprising combination of elements that correlates to the elected Group.

The inventions are distinct, each from the other for the following reasons.

The inventions of Group I-IV are patentably distinct because the inventions are drawn to structurally distinct compositions. The vector constructs of Group I-III comprising different elements. These sequences are thus deemed to normally constitute independent and distinct

Application/Control Number: 09/845,064

Art Unit: 1636

inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. Accordingly, in most cases, only one (1) independent and distinct nucleotide sequence will be examined in a single application without restriction.

The inventions of Group I-IV are patentably distinct from the inventions of Group V because the inventions are drawn to materially distinct compositions. The vectors of Group I-IV are structurally, chemically and biologically distinct from the transgenic plant of Group V.

Therefore, the inventions of Group I-IV are patentably distinct from the invention of Group V.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. A search of the entire groups is not co-extensive and burdensome.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The examiner can normally be reached on 9:00-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Art Unit: 1636

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D. July 1, 2002

> REMYYUCEL, PH.D SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600